Wall Street brokerages expect Natera Inc (NASDAQ:NTRA) to announce earnings per share (EPS) of ($0.41) for the current quarter, Zacks reports. Three analysts have provided estimates for Natera’s earnings, with the lowest EPS estimate coming in at ($0.45) and the highest estimate coming in at ($0.38). Natera posted earnings of ($0.73) per share during the same quarter last year, which would indicate a positive year over year growth rate of 43.8%. The firm is expected to announce its next quarterly earnings results on Tuesday, March 12th.
On average, analysts expect that Natera will report full year earnings of ($2.09) per share for the current financial year, with EPS estimates ranging from ($2.19) to ($1.98). For the next year, analysts forecast that the company will post earnings of ($1.13) per share, with EPS estimates ranging from ($1.39) to ($0.96). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that follow Natera.
Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, November 8th. The medical research company reported ($0.49) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.03). Natera had a negative net margin of 59.07% and a negative return on equity of 752.93%. The firm had revenue of $65.30 million during the quarter, compared to the consensus estimate of $66.42 million. During the same period in the previous year, the business earned ($0.51) earnings per share. The firm’s revenue for the quarter was up 16.8% on a year-over-year basis.
Several research analysts have commented on the stock. BidaskClub downgraded shares of Natera from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 30th. Cowen reissued a “buy” rating and issued a $30.00 price target on shares of Natera in a report on Friday. Piper Jaffray Companies raised their price target on shares of Natera to $27.00 and gave the company an “overweight” rating in a report on Thursday, August 9th. Zacks Investment Research raised shares of Natera from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a report on Tuesday, July 17th. Finally, TheStreet downgraded shares of Natera from a “c-” rating to a “d+” rating in a report on Tuesday, October 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Natera currently has a consensus rating of “Buy” and a consensus target price of $28.25.
In other news, COO Steven Leonard Chapman sold 45,000 shares of Natera stock in a transaction on Tuesday, September 11th. The shares were sold at an average price of $25.16, for a total transaction of $1,132,200.00. Following the completion of the sale, the chief operating officer now directly owns 16,628 shares of the company’s stock, valued at approximately $418,360.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jonathan Sheena sold 166,667 shares of Natera stock in a transaction on Tuesday, October 16th. The stock was sold at an average price of $20.66, for a total transaction of $3,443,340.22. Following the sale, the insider now directly owns 372,583 shares of the company’s stock, valued at $7,697,564.78. The disclosure for this sale can be found here. Over the last three months, insiders sold 2,014,988 shares of company stock valued at $48,674,710. Insiders own 13.18% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Alliancebernstein L.P. lifted its holdings in shares of Natera by 7.3% during the 3rd quarter. Alliancebernstein L.P. now owns 41,000 shares of the medical research company’s stock worth $982,000 after acquiring an additional 2,800 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Natera by 6.9% during the 3rd quarter. Wells Fargo & Company MN now owns 52,899 shares of the medical research company’s stock worth $1,266,000 after acquiring an additional 3,411 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Natera by 1.5% during the 1st quarter. Northern Trust Corp now owns 375,674 shares of the medical research company’s stock worth $3,483,000 after acquiring an additional 5,428 shares during the last quarter. Asymmetry Capital Management L.P. lifted its holdings in shares of Natera by 4.8% during the 3rd quarter. Asymmetry Capital Management L.P. now owns 124,517 shares of the medical research company’s stock worth $2,981,000 after acquiring an additional 5,648 shares during the last quarter. Finally, State of Wisconsin Investment Board lifted its holdings in shares of Natera by 30.4% during the 2nd quarter. State of Wisconsin Investment Board now owns 30,000 shares of the medical research company’s stock worth $565,000 after acquiring an additional 7,000 shares during the last quarter. 67.46% of the stock is owned by institutional investors.
Shares of NASDAQ:NTRA opened at $16.80 on Friday. Natera has a one year low of $8.60 and a one year high of $29.62. The firm has a market capitalization of $1.29 billion, a price-to-earnings ratio of -7.00 and a beta of 2.11.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Further Reading: Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.